National Drug Rehab Authority

Drug Rehab: What It Is and Why It Matters

Drug rehabilitation — the clinical, social, and behavioral process of treating substance use disorders — is one of the most consequential and most misunderstood corners of American healthcare. This page establishes what drug rehab actually is, how its core mechanisms work, where the public tends to get tripped up, and what falls outside the definition. The site behind this page covers over 80 published reference pages, from facility accreditation standards and federal OTP regulations to cost comparisons and behavioral therapy protocols — organized to serve anyone who needs real answers, not a sales pitch.

Core moving parts

Substance use disorder is classified as a chronic brain disease by the American Society of Addiction Medicine (ASAM), which means drug rehab is not a one-time event. It is a structured clinical process — sometimes measured in weeks, often in months, occasionally in years — designed to interrupt compulsive drug use, address the underlying drivers of addiction, and build a sustainable path to recovery.

The process typically unfolds in stages:

This site, part of the broader Authority Network America (authoritynetworkamerica.com), covers each of these stages in dedicated reference pages — from evidence-based therapies to adolescent-specific treatment standards.

Where the public gets confused

The biggest source of confusion is the word "rehab" itself. It gets applied to 28-day luxury programs, 3-day detox stays billed as rehabilitation, court-ordered community service programs with no clinical staff, and rigorous 90-day residential programs with psychiatric oversight — all at once. These are not equivalent.

The detox-versus-treatment distinction is particularly important. A facility that offers only medical detoxification is not providing drug rehabilitation in the clinical sense. Detox clears the substance from the body. Rehab addresses why the person used it and how they'll live without it. Conflating the two is how people end up cycling through "treatment" that never treats anything.

The Drug Rehab: Frequently Asked Questions page on this site addresses the most common points of confusion — including what accreditation actually means, when inpatient is clinically necessary versus simply more expensive, and how to read a program's success rate claims with appropriate skepticism.

Another persistent confusion: "faith-based" versus "evidence-based" is not a binary. A program can incorporate spiritual elements while also delivering CBT and MAT. What matters clinically is whether licensed professionals are providing evidence-based care — not what the facility hangs on its walls.

Boundaries and exclusions

Drug rehab does not include:

The regulatory footprint

Drug rehab in the United States operates under a layered patchwork of federal and state oversight — which is a polite way of saying the regulatory landscape is genuinely complicated and varies significantly by geography and service type.

At the federal level, opioid treatment programs (OTPs) — facilities that dispense methadone for opioid use disorder — are regulated by the Substance Abuse and Mental Health Services Administration (SAMHSA) under 42 CFR Part 8. These programs must be federally certified and accredited by a SAMHSA-approved body. Facilities prescribing buprenorphine operate under the Drug Enforcement Administration's Schedule III controlled substance framework, with prescriber requirements modified by the Mainstreaming Addiction Treatment (MAT) Act enacted in 2023.

State licensing requirements for residential and outpatient drug rehab programs are set independently by each of the 50 states and vary substantially — in staffing ratios, inspection frequency, and minimum clinical standards. The Drug Rehab Facility Accreditation and Licensing Standards in the US page on this site maps the major accrediting bodies: The Joint Commission, CARF International, and the Commission on Accreditation of Rehabilitation Facilities each operate distinct standards frameworks that facilities can pursue independently of state licensure.

The Affordable Care Act's mental health and substance use disorder parity provisions — codified under the Mental Health Parity and Addiction Equity Act (MHPAEA) — require that insurance coverage for substance use disorder treatment be no more restrictive than coverage for medical or surgical conditions. Enforcement has been inconsistent, but the statutory obligation is clear and applies to most employer-sponsored and individual market health plans.

· ·

References

Read Next

Drug Rehab: Frequently Asked Questions ANA › Life Services Authority › National Drugrehab Drug Rehab: Frequently Asked Questions Drug rehabilitation is one of those subjects... How to Get Help for Drug Rehab ANA › Life Services Authority › National Drugrehab How to Get Help for Drug Rehab Reaching out for drug rehabilitation support is one of... 12-Step Programs in Drug Rehab: Clinical Integration and Limitations ANA › Life Services Authority › National Drugrehab 12-Step Programs in Drug Rehab: Clinical Integration and Limitations Twelve-step...

Live network data

DEA Drug Scheduling (2024)

5

controlled-substance schedules · 1,900,000 DEA registrants · 1,700,000 practitioners · 73,000 pharmacies

Schedule I: 264 substances (heroin, LSD, MDMA, cannabis, peyote, psilocybin)

Schedule II: 156 (oxycodone, fentanyl, methadone, methamphetamine, cocaine, amphetamine)

Schedule III: 84 (codeine combinations, ketamine, anabolic steroids, buprenorphine)

Schedule IV: 89 (alprazolam, diazepam, tramadol, zolpidem)

Schedule V: 21 (cough preparations <200mg codeine/100mL, pregabalin, lacosamide)

Overdose by Substance (CDC NCHS 2023)

105,007

total US overdose deaths · -3.0% YoY · 31.3 per 100K · 77.2% opioid-involved

Synthetic opioid (fentanyl): 73,838 (70.3%)

Cocaine: 28,338 · Methamphetamine: 36,251

Heroin: 5,872 · Methadone: 3,088

Polysubstance: 60.0%

Highest state (West Virginia): 80.9 per 100K

Treatment Capacity (SAMHSA N-SSATS 2024)

17,500

SUD treatment facilities · 3,900 with residential beds · ~75,000 total beds · 88.0% utilization

Outpatient-only: 86.0%

MAT (buprenorphine): 65.0%

MAT (methadone OTPs): 2,086 facilities

Buprenorphine practitioners: 124,000

Accepting Medicaid: 75.0%

Offering telehealth: 91.0%

Treatment Admissions (TEDS-A 2022)

1,672K

total admissions · 65.0% male · 56.0% age 25-44 · 47.0% completed treatment

Alcohol only: 28.0% · Heroin: 13.0%

Other opioids/synthetic: 12.0% · Meth: 12.0%

Cocaine: 6.0% · Marijuana: 10.0%

Co-occurring mental disorder: 50.0%

Referred by criminal justice: 27.0%

Harm Reduction (2024)

250,000

estimated overdose reversals via naloxone/yr · 1.5M kits distributed · OTC since 2023-09 (Narcan OTC FDA approval)

States with naloxone pharmacy standing order: 50/50

States with Good Samaritan laws: 49/50

Syringe services programs: 380 in 41 states

Counties with buprenorphine provider: 76.0%

Counties with methadone clinic: 27.0%

Source: DEA Scheduling 2024 + CDC NCHS Drug Overdose 2023 + SAMHSA N-SSATS 2024 + TEDS-A 2022 + CDC + NIDA Harm Reduction 2024

Aggregated 2026-04-30T14:24:25Z